Search
Sufentanil
go.drugbank.com/drugs/DB00708ApprovedInvestigationalSufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. … (AcelRx), was approved on November 2, 2018 [L4717].
Phenelzine
go.drugbank.com/drugs/DB00780ApprovedInvestigational[A15753] It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name of Nardil.
Oxymetholone
go.drugbank.com/drugs/DB06412ApprovedIllicitAnabolic-androgenic steroids (AAS), such as oxymetholone, have been abused by bodybuilders and athletes. … In 2009, no producers of oxymetholone were identified worldwide (SRI 2009), but it was available from 14 suppliers, including 8 U.S. suppliers (ChemSources 2009).
Nusinersen
go.drugbank.com/drugs/DB13161ApprovedInvestigationalFDA in December, 2016 as Spinraza for the treatment of children and adults with spinal muscular atrophy (SMA). It is adminstrated as direct intrathecal injection. … An antisense oligonucleotide that induces survival motor neuron (SMN) protein expression, it was approved by the U.S.
Lumateperone
go.drugbank.com/drugs/DB06077ApprovedInvestigational[A189093] Further, not only is the new antipsychotic selective for dopamine (D2) receptors in the mesolimbic and mesocortical brain regions, but it also has minimal off-target activity. … [A189093] It has a unique receptor binding profile and differs from other antipsychotics in that it modulates glutamate, serotonin and dopamine, which are all neurotransmitters that contribute to the pathophysiology
Protein S human
go.drugbank.com/drugs/DB13149ApprovedInvestigationalProtein S human is a vitamin K-dependent plasma glycoprotein which has antcoagulant properties [A19561]. It serves as a negative feedback mechanism in the coagulation cascade.
Medrogestone
go.drugbank.com/drugs/DB09124ApprovedWithdrawn[L1118] It was never approved by the FDA. … It was conceived as an alternative for an orally effective contraceptive option.[A31526] It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing.
Carisoprodol
go.drugbank.com/drugs/DB00395ApprovedIn January 2012, this drug was classified as a Schedule IV substance under the controlled substances act in several US states due to alarming rates of abuse [A176062, A176077] despite having a low potential
Tasonermin
go.drugbank.com/drugs/DB11626Approvedof the limbs as the product Beromun. … It was approved for use by the European Medicines Agency in April of 1999 for use as an adjunt to surgery for the subsequent removal of the tumor and in palliative care for irresectable soft tissue sarcoma
Inulin
go.drugbank.com/drugs/DB00638ApprovedInvestigationalNutraceuticalSince it is hydrolyzable to fructose, it is classified as a fructosan. It has been used in physiologic investigation for determination of the rate of glomerular function.